Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1607 • ACR Convergence 2021
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
Rebecca Sadun¹, Mithu Maheswaranathan¹, Megan Clowse², Kai Sun¹, Jennifer Rogers¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
Abstract Number: 1733 • ACR Convergence 2021
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
Martin Aringer¹, Ian N. Bruce², Richard Furie³, Eric Morand⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁷, ¹University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 1771 • ACR Convergence 2021
First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
Melanie Harrison¹, Manoj Chiney¹, Diane Shevell², Lixian Dong³, Michelle Dawes¹ and Ihab Girgis³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Lawrenceville, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Toll-like receptor (TLR)7 and TLR8 are endosomal receptors that are normally activated by pathogen-associated RNA. They are also activated by self-RNA as part of…
Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…
Abstract Number: 0331 • ACR Convergence 2021
Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
Hiroki Yamaguchi¹, Yoriko Ando¹, Mika Mizunuma¹, Masamichi Inami², Kenichi Suzumura² and Yuki Ichikawa¹, ¹Craif Inc., Nagoya, Japan, ²Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, immune complex deposition, and heterogeneous clinical manifestations affecting many organs, including…
Abstract Number: 0348 • ACR Convergence 2021
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴, Zahi Touma⁵ and Sindhu Johnson⁶, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: We recently demonstrated that a EULAR/ACR classification Criteria score ≥ 20 predicts a higher disease activity throughout the first 5 years after diagnosis. Given…
Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Asmaa AbuMaziad¹, Abhimanyu Amarnani² and Ram Singh³, ¹University of California Los Angeles, Los Angeles, CA, ²Los Angeles County + University of Southern California, Los Angeles, CA, ³University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
Abstract Number: 0623 • ACR Convergence 2021
Intervention to Improve SLE Medication Adherence
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Mithu Maheswaranathan¹, Ann Barr², Lena Eder³, Amy Corneli¹, Hayden Bosworth² and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Both the under-recognition of nonadherence…
Abstract Number: 0855 • ACR Convergence 2021
Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Pamela Munguía-Realpozo², Karla Godinez-Bolaños², Mario García-Carrasco², Ivet Etchegaray-Morales² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To date, the prevalence and prognosis of coronary artery disease (CAD) according to the coronary calcium score (CCS) and coronary artery calcification (CAC) using…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0889 • ACR Convergence 2021
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Andrea Knight⁴, Juan Diaz-Martinez⁵, Kathleen Bingham⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁶, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵UHN, Toronto, ON, Canada, ⁶University of Toronto, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a number of neuropsychiatric manifestations including cognitive impairment (CI). Previous meta-analyses have reported the prevalence of CI…
Abstract Number: 0994 • ACR Convergence 2021
Role of SLE Associated Cytokines in Generation of Mature Neutrophils
Neelakshi R. Jog, Julia Nguyen and Judith James, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].